List of Excipients in Branded Drug ADVIL LIQUI-GELS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lil' Drug Store Products Inc	ADVIL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-6552	FD&C GREEN NO. 3
Lil' Drug Store Products Inc	ADVIL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-6552	GELATIN
Lil' Drug Store Products Inc	ADVIL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-6552	LECITHIN, SOYBEAN
Lil' Drug Store Products Inc	ADVIL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-6552	MEDIUM-CHAIN TRIGLYCERIDES

Advil Liqui-Gels Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: October 22, 2026

Advil Liqui-Gels is an OTC ibuprofen softgel product whose commercial value depends on rapid disintegration, dose uniformity, consumer recognition, and reliable gelatin-capsule manufacturing. The core opportunity is not protection of ibuprofen itself. It is differentiation through excipient systems, capsule materials, release performance, packaging, supply-chain resilience, and consumer attributes such as animal-free composition or improved swallowability.

What is the Advil Liqui-Gels formulation?

Advil Liqui-Gels contains 200 mg of ibuprofen in a liquid-filled soft gelatin capsule. The U.S. Drug Facts labeling identifies excipients that include gelatin, polyethylene glycol, sorbitol, purified water, potassium hydroxide, lecithin, medium-chain triglycerides, mineral oil, and colorants or printing materials, depending on the specific product presentation and market configuration.[1]

Formulation element	Commercial function	Strategic relevance
Ibuprofen	Active pharmaceutical ingredient	Commodity API with broad supplier availability
Gelatin shell	Encapsulation, mechanical strength, consumer appearance	Creates animal-origin and supply-chain constraints
Polyethylene glycol	Solvent or cosolvent for liquid fill	Supports ibuprofen solubilization and fill uniformity
Sorbitol	Plasticizer and moisture-control component	Affects shell flexibility and brittleness
Purified water	Processing and shell component	Requires moisture control during manufacture
Potassium hydroxide	pH adjustment and potential solubilization support	Affects chemical stability and fill compatibility
Lecithin	Wetting and emulsification support	Can improve fill-process behavior
Medium-chain triglycerides	Lipid vehicle	Supports liquid fill and mouthfeel
Mineral oil	Processing or formulation support	May create label, sourcing, and consumer-perception issues
Colorants and ink	Product identification and branding	Supports anti-counterfeiting and visual differentiation

The precise excipient composition can vary by product strength, package, manufacturing site, country, and label revision. A formulation comparison should therefore use the current package insert and the applicable regulatory filing rather than historical product literature.

What excipient strategy supports an Advil Liqui-Gels competitor?

The strongest strategy is a platform approach that separates the liquid fill, capsule shell, and packaging claims.

Liquid-fill strategy

A competitor can evaluate:

• Polyethylene glycol and lower-viscosity cosolvent systems
• Medium-chain triglyceride vehicles
• Mixed lipid and polar-solvent systems
• Non-aqueous fills with reduced hydrolytic risk
• pH-adjusted ibuprofen solutions or suspensions
• Reduced-excipient systems with fewer declaration lines
• Fill systems compatible with high-speed rotary-die encapsulation

Ibuprofen has limited water solubility. A liquid-filled capsule can therefore provide a manufacturing and consumer-use advantage over conventional compressed tablets, but the fill must maintain chemical stability and prevent precipitation during storage.

Key development measurements include:

Attribute	Development target
Ibuprofen assay	Within applicable OTC finished-product limits
Fill uniformity	Consistent dose across capsules and batches
Viscosity	Compatible with pump and die-roll equipment
Capsule leakage	No material leakage through shelf life
Disintegration	Consistent performance under approved testing conditions
Dissolution	Comparable or superior release versus the reference product
Shell brittleness	No cracking under temperature and humidity stress
Peroxide and impurity control	Controlled degradation in lipid or PEG components
Microbial quality	Compliant with finished-product requirements
Stability	Meets labeled shelf life in commercial packaging

The principal commercial opportunity is a formulation with comparable consumer performance but a simpler excipient profile, improved stability, or lower manufacturing cost.

Capsule-shell strategy

Gelatin remains effective because it forms strong, elastic shells and is established for softgel manufacturing. It also creates several opportunities:

1. Animal-free softgels using modified starch, carrageenan, pullulan, or other hydrocolloid systems.
2. Lower-moisture shells for improved stability of moisture-sensitive fills.
3. Clear or translucent shells that reduce colorant use.
4. Tamper-evident shells or differentiated capsule geometry.
5. Shell systems that reduce brittleness during cold-chain or winter distribution.

Plant-based softgels can command a premium, but they introduce technical risks. Non-gelatin shells may have narrower processing windows, greater sensitivity to humidity, higher equipment-conversion costs, and different dissolution behavior. A successful platform must match gelatin performance across temperature, humidity, storage, and transportation conditions.

What formulation patents could protect a competing Liqui-Gel product?

The most defensible formulation claims would focus on combinations and performance limits rather than broad claims to ibuprofen in a softgel.

Potential claim categories include:

Claim category	Example protection focus
Liquid fill	Ibuprofen concentration, solvent ratio, lipid content, viscosity range
Chemical stability	Impurity limits after accelerated storage
Capsule shell	Gelatin or non-gelatin composition, plasticizer ratio, moisture content
Release profile	Disintegration or dissolution within defined time limits
Manufacturing process	Deaeration, temperature control, encapsulation, drying, curing
Fill-shell compatibility	Reduced migration, reduced leakage, lower shell interaction
Packaging	Moisture barrier, oxygen barrier, blister structure, bottle desiccant
Consumer attributes	Animal-free, allergen-reduced, colorant-free, swallowability
Combination products	Ibuprofen with a second active ingredient, if regulatory requirements are met

A patent application should include broad and narrow composition ranges, multiple solvent systems, capsule-shell alternatives, process parameters, stability data, and comparative dissolution results. A single narrow example can be designed around by changing the solvent ratio, shell plasticizer, or packaging configuration.

The strongest patent estate would combine:

• Composition claims for the liquid fill
• Capsule-shell claims
• Process claims
• Packaging claims
• Method-of-use claims where legally available
• Continuation applications directed to commercially important fallbacks

What patent protection applies to Advil Liqui-Gels?

Ibuprofen is an old active ingredient and does not provide meaningful new-molecule exclusivity for Advil Liqui-Gels. The commercial product is primarily protected by trademark, brand recognition, manufacturing know-how, regulatory compliance, packaging, and potential formulation or process patents.

Advil is associated with Haleon and its predecessor companies. Public OTC labeling identifies the product and its manufacturer or distributor, but an accurate patent analysis requires a current review of USPTO assignments, Google Patents or equivalent records, FDA submissions, litigation databases, and product-specific patent families.

Is Advil Liqui-Gels listed in the Orange Book?

OTC ibuprofen products may be marketed under the FDA’s OTC monograph framework rather than relying on an approved NDA with Orange Book patent exclusivity. Ibuprofen products are covered by the FDA framework for internal analgesic, antipyretic, and antirheumatic drug products, subject to applicable conditions and labeling requirements.[2]

This has four commercial consequences:

• Orange Book patent listings may not be the primary barrier to entry.
• Paragraph IV certification is generally associated with ANDA litigation and is not the standard route for a monograph-compliant OTC product.
• A competitor can often enter by meeting monograph requirements rather than waiting for brand patent expiration.
• Formulation patents, trademarks, trade dress, manufacturing know-how, and channel access become more important than Orange Book-listed patents.

A product-specific patent search should not assume that the absence of an Orange Book listing means the absence of enforceable intellectual-property rights. Separate patents may cover a formulation, manufacturing method, packaging system, or device.

When does Advil Liqui-Gels lose exclusivity?

There is no single small-molecule exclusivity date equivalent to the expiration of a modern NDA’s new chemical entity period for an established OTC ibuprofen softgel.

Protection type	Status for Advil Liqui-Gels
Ibuprofen composition-of-matter exclusivity	Expired for decades
FDA new chemical entity exclusivity	Not commercially relevant to this old active
OTC monograph access	Available subject to compliance
Trademark protection	Ongoing while maintained and used
Trade dress	Potentially ongoing, subject to scope and enforcement
Formulation patents	Must be assessed by patent family and expiration date
Process patents	Must be assessed separately
Orange Book exclusivity	Not the central entry mechanism for monograph ibuprofen
Biosimilar exclusivity	Not applicable

Generic or store-brand ibuprofen softgels can enter without waiting for a brand exclusivity period if they satisfy applicable FDA requirements and do not infringe enforceable rights.

What generic entry risks exist for Advil Liqui-Gels?

Generic entry risk is high at the active-ingredient level and moderate at the dosage-form level.

High-risk areas

• Ibuprofen API sourcing
• Standard 200 mg tablets and capsules
• Conventional liquid-filled softgels
• Retail private-label products
• E-commerce products using comparable dosage forms
• Price competition during retailer promotions

More defensible areas

• Recognizable branded softgel geometry
• Proprietary capsule-shell technology
• Animal-free or specialty softgels
• Rapid-release performance supported by comparative data
• Child-resistant or senior-friendly packaging
• Combination products with a distinct regulatory pathway
• Manufacturing systems with difficult-to-replicate process controls

A generic product does not need to duplicate every Advil excipient. It must meet applicable quality, safety, labeling, and performance requirements. This creates room for competitors to avoid a branded formulation while preserving the consumer benefit of a liquid-filled capsule.

What commercial opportunities exist in excipient redesign?

Animal-free and clean-label softgels

A plant-based softgel could target consumers who avoid bovine or porcine gelatin. The opportunity is strongest in natural-product, vegetarian, religious-compliance, and premium retail channels.

The main risks are shell performance, manufacturing throughput, moisture sensitivity, and consumer acceptance of a different capsule appearance.

Reduced-excipient products

A simplified formulation may reduce procurement complexity and improve label readability. The commercial benefit depends on whether the reduction affects product stability, capsule integrity, or manufacturing yield.

A lower-component system can also reduce supply risk. This is relevant when a product depends on specialized grades of PEG, sorbitol, gelatin, or colorant.

Colorant-free and transparent products

A clear capsule can support a clean-label positioning and allow visual inspection of the liquid fill. It may require new branding and anti-counterfeiting controls because color is often part of consumer product recognition.

Improved packaging

Packaging is a practical area for differentiation. Potential approaches include:

• High-barrier blister packs
• Unit-dose packaging for travel and institutional sales
• Child-resistant bottles
• Senior-friendly closures
• Desiccant-integrated bottles
• Reduced-plastic packaging
• Serialized packaging for supply-chain authentication

Packaging patents may be easier to enforce against a directly copying competitor than broad excipient claims, although their commercial value depends on actual adoption.

Manufacturing and licensing

A company with a validated softgel process, non-gelatin shell, or stable ibuprofen fill can license:

• Formulation technology
• Shell materials
• Encapsulation equipment settings
• Contract manufacturing capacity
• Analytical methods
• Stability packages
• Regulatory documentation

Potential counterparties include generic manufacturers, consumer-health companies, regional OTC marketers, and private-label retailers.

How strong is the Advil Liqui-Gels patent estate?

The product’s strategic strength is likely greater in brand and execution than in basic formulation exclusivity. Ibuprofen softgel technology is commercially mature, and broad claims covering ibuprofen in a liquid-filled capsule would face substantial prior-art exposure.

A practical strength assessment is:

Asset	Relative strength
Ibuprofen active ingredient	Low
General softgel dosage form	Low
Specific fill composition	Moderate if supported by stability and performance data
Non-gelatin shell	Moderate to high if technically differentiated
Manufacturing process	Moderate, with enforcement dependent on evidence
Packaging configuration	Moderate
Advil trademark	High within the relevant OTC analgesic market
Consumer recognition	High, but not patent protection
Retail distribution	High commercial value, limited patent value

Patent strength should be measured by claim breadth, validity over prior art, ease of detecting infringement, remaining term, geographic coverage, and commercial dependence on the claimed feature.

What geographic opportunities exist?

The U.S. market is governed by FDA OTC requirements and monograph conditions. Other markets may impose different requirements for ibuprofen dosage forms, excipients, labeling, gelatin origin, colorants, and permissible health claims.

Priority markets include:

• United States: large OTC market and strong brand competition
• Canada: established ibuprofen category with bilingual packaging requirements
• European Union: country-specific OTC distribution and excipient-labeling rules
• United Kingdom: separate post-Brexit regulatory processes
• Australia: regulated nonprescription analgesic market
• Middle East and Southeast Asia: potential demand for halal or animal-origin-compliant softgels
• Latin America: private-label and regional-brand opportunities

Animal-origin documentation can be commercially important in Muslim-majority markets. A non-gelatin platform may simplify market positioning, but local regulatory acceptance and manufacturing validation remain necessary.

Does biosimilar risk affect Advil Liqui-Gels?

No. Biosimilar competition is irrelevant because Advil Liqui-Gels contains ibuprofen, a chemically synthesized small molecule. The relevant competitors are generic ibuprofen products, private-label OTC products, branded analgesics, topical NSAIDs, acetaminophen products, and combination medicines.

What litigation and settlement issues matter?

The principal litigation risks are likely to involve trademarks, trade dress, advertising claims, product liability, manufacturing quality, and formulation or process patents rather than Paragraph IV challenges to a new-molecule NDA.

A competitive diligence program should review:

• Federal trademark disputes involving Advil or capsule appearance
• Patent cases involving ibuprofen softgels
• FDA warning letters and recalls
• Consumer class actions concerning labeling or inactive ingredients
• Product-liability cases involving NSAID risks
• Retailer disputes over private-label positioning
• Settlement agreements that restrict launch timing or marketing claims

No commercial launch should rely solely on an Orange Book review. OTC products require a broader freedom-to-operate analysis.

Key Takeaways

• Advil Liqui-Gels is a 200 mg ibuprofen liquid-filled softgel product.
• The main excipient opportunities involve the liquid fill, capsule shell, packaging, and manufacturing process.
• Gelatin replacement is the clearest premium opportunity but carries technical and manufacturing risks.
• Ibuprofen has no meaningful remaining composition-of-matter exclusivity.
• OTC monograph entry reduces the relevance of Orange Book exclusivity and Paragraph IV litigation.
• Generic competition is structurally strong, especially for standard ibuprofen products.
• Brand, trademark, retail placement, and consumer recognition may provide greater protection than broad formulation patents.
• A defensible patent portfolio should combine composition, shell, process, packaging, and stability claims.
• Biosimilar risk does not apply.
• Regional opportunities include halal, vegetarian, clean-label, senior-friendly, and sustainable packaging segments.

FAQs

Can a competitor use the same Advil Liqui-Gels excipients?

Yes, unless a specific formulation, process, or packaging claim remains enforceable. Excipients themselves are generally not proprietary merely because they appear on a product label.

Is a liquid-filled ibuprofen capsule patentable?

Potentially, but a broad claim to ibuprofen in a softgel would face prior-art challenges. Patentability is stronger for a defined excipient ratio, shell system, stability profile, release characteristic, or manufacturing process.

Can a private-label retailer launch ibuprofen Liqui-Gels?

Yes, subject to FDA requirements, applicable OTC monograph conditions, labeling rules, quality controls, and freedom-to-operate review.

Are gelatin-free ibuprofen softgels commercially viable?

Yes. They can target vegetarian, halal, kosher, and clean-label segments, but the shell must meet mechanical, stability, encapsulation, and dissolution requirements.

What is the most valuable excipient innovation for an ibuprofen softgel?

A stable, scalable, non-gelatin capsule platform with reliable rapid release and a lower-complexity liquid fill offers the broadest commercial value.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Advil Liqui-Gels, ibuprofen liquid filled capsule labeling. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
3. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.
4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.
6. Haleon plc. (2024). Annual report and financial statements. Haleon.